Mersana Therapeutics (NASDAQ: MRSN) issues Q3 2025 business and results press release

Rhea-AI Filing Summary

Mersana Therapeutics, Inc. filed a current report stating that it issued a press release with business updates and financial results for the fiscal quarter ended September 30, 2025. The company’s common stock trades on The Nasdaq Stock Market under the symbol MRSN. The press release is included as Exhibit 99.1, while Exhibit 104 covers the interactive data for the cover page. The company notes that the information in this earnings-related item and the attached exhibit is being furnished, not filed, which limits its exposure to certain Exchange Act liabilities and controls how it may be incorporated by reference into other SEC documents.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

false 0001442836 0001442836 2025-11-14 2025-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 14, 2025

MERSANA THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38129		04-3562403
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

840 Memorial Drive Cambridge, Massachusetts		02139
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s telephone number, including area code: (617) 498-0020

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨         Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨         Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨         Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨         Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value	MRSN	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition. 

On November 14, 2025, Mersana Therapeutics, Inc. (the “Company”) issued a press release announcing business updates and financial results for the fiscal quarter ended September 30, 2025.

The information furnished in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing by the Company with the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, regardless of any general incorporation language contained in such filing, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release issued by the Company on November 14, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MERSANA THERAPEUTICS, INC.
Date: November 14, 2025	By:	/s/ Brian DeSchuytner
		Brian DeSchuytner
		Senior Vice President, Chief Operating Officer and Chief Financial Officer

FAQ

What did Mersana Therapeutics (MRSN) disclose in this 8-K filing?

Mersana Therapeutics disclosed that it issued a press release providing business updates and financial results for the fiscal quarter ended September 30, 2025, which is attached as Exhibit 99.1.

Which period’s results are referenced in Mersana Therapeutics’ latest update?

The press release referenced in the filing covers financial results for the fiscal quarter ended September 30, 2025.

How is the earnings information in this MRSN filing treated under SEC rules?

The company states that the information in Item 2.02 and Exhibit 99.1 is furnished and not filed, so it is not subject to Section 18 liability and is only incorporated into other SEC filings if specifically referenced.

What exhibits are included with this Mersana Therapeutics 8-K?

The filing includes Exhibit 99.1, a press release issued November 14, 2025, and Exhibit 104, the cover page interactive data file embedded in the Inline XBRL document.

On which exchange does Mersana Therapeutics’ common stock trade?

Mersana Therapeutics’ common stock, par value $0.0001 per share, trades on The Nasdaq Stock Market LLC under the symbol MRSN.

Who signed the Mersana Therapeutics 8-K for the company?

The report was signed on behalf of the company by Brian DeSchuytner, who serves as Senior Vice President, Chief Operating Officer and Chief Financial Officer.